UBS AM’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $447M | Sell |
716,560
-7,061
| -1% | -$4.81M | 0.08% | 204 |
|
|
2026
Q1 | $559M | Sell |
723,621
-21,612
| -3% | -$16.5M | 0.12% | 158 |
|
|
2025
Q4 | $575M | Buy |
745,233
+1,060
| +0.1% | +$720K | 0.12% | 139 |
|
|
2025
Q3 | $418M | Sell |
744,173
-116,268
| -14% | -$65.7M | 0.09% | 200 |
|
|
2025
Q2 | $452M | Sell |
860,441
-79,895
| -8% | -$44.6M | 0.09% | 214 |
|
|
2025
Q1 | $596M | Sell |
940,336
-41,728
| -4% | -$28.7M | 0.15% | 134 |
|
|
2024
Q4 | $700M | Buy |
982,064
+226,952
| +30% | +$190M | 0.16% | 116 |
|
|
2024
Q3 | $794M | Sell |
755,112
-92,570
| -11% | -$103M | 0.2% | 90 |
|
|
2024
Q2 | $891M | Buy |
847,682
+163,118
| +24% | +$158M | 0.26% | 71 |
|
|
2024
Q1 | $659M | Buy |
684,564
+18,183
| +3% | +$17.3M | 0.23% | 78 |
|
|
2023
Q4 | $585M | Sell |
666,381
-29,006
| -4% | -$23.9M | 0.23% | 80 |
|
|
2023
Q3 | $572M | Buy |
695,387
+29,203
| +4% | +$23M | 0.26% | 76 |
|
|
2023
Q2 | $547M | Hold |
666,184
| – | – | 0.27% | 77 |
|
|
2023
Q1 | $547M | Buy |
666,184
+58,828
| +10% | +$44.4M | 0.27% | 77 |
|
|
2022
Q4 | $438M | Buy |
607,356
+6,362
| +1% | +$4.69M | 0.23% | 94 |
|
|
2022
Q3 | $414M | Sell |
600,994
-2,554
| -0.4% | -$1.61M | 0.23% | 89 |
|
|
2022
Q2 | $357M | Buy |
603,548
+27,385
| +5% | +$17.8M | 0.19% | 117 |
|
|
2022
Q1 | $402M | Sell |
576,163
-31,755
| -5% | -$20.1M | 0.17% | 120 |
|
|
2021
Q4 | $384M | Buy |
607,918
+83,707
| +16% | +$51.5M | 0.15% | 146 |
|
|
2021
Q3 | $317M | Sell |
524,211
-49,007
| -9% | -$30.4M | 0.13% | 163 |
|
|
2021
Q2 | $320M | Sell |
573,218
-45,128
| -7% | -$22.9M | 0.14% | 160 |
|
|
2021
Q1 | $293M | Sell |
618,346
-25,096
| -4% | -$12.2M | 0.13% | 164 |
|
|
2020
Q4 | $311M | Buy |
643,442
+51,243
| +9% | +$27.7M | 0.15% | 141 |
|
|
2020
Q3 | $332M | Buy |
592,199
+90,142
| +18% | +$54.7M | 0.18% | 113 |
|
|
2020
Q2 | $313M | Buy |
502,057
+167,966
| +50% | +$95.3M | 0.19% | 110 |
|
|
2020
Q1 | $163M | Buy |
334,091
+2,841
| +0.9% | +$1.17M | 0.12% | 179 |
|
|
2019
Q4 | $124M | Sell |
331,250
-2,667
| -0.8% | -$897K | 0.08% | 273 |
|
|
2019
Q3 | $92.6M | Sell |
333,917
-74,874
| -18% | -$22.2M | 0.06% | 330 |
|
|
2019
Q2 | $128M | Sell |
408,791
-892
| -0.2% | -$297K | 0.09% | 244 |
|
|
2019
Q1 | $168M | Buy |
409,683
+85,327
| +26% | +$35.1M | 0.12% | 183 |
|
|
2018
Q4 | $121M | Buy |
324,356
+6,070
| +2% | +$2.22M | 0.1% | 216 |
|
|
2018
Q3 | $129M | Sell |
318,286
-22,172
| -7% | -$8.44M | 0.1% | 238 |
|
|
2018
Q2 | $117M | Sell |
340,458
-634
| -0.2% | -$198K | 0.09% | 254 |
|
|
2018
Q1 | $117M | Sell |
341,092
-212,409
| -38% | -$73.9M | 0.09% | 253 |
|
|
2017
Q4 | $208M | Buy |
553,501
+267,442
| +93% | +$108M | 0.18% | 123 |
|
|
2017
Q3 | $128M | Sell |
286,059
-7,269
| -2% | -$3.46M | 0.12% | 195 |
|
|
2017
Q2 | $144M | Buy |
293,328
+5,562
| +2% | +$2.43M | 0.14% | 170 |
|
|
2017
Q1 | $112M | Sell |
287,766
-40,035
| -12% | -$14.8M | 0.11% | 206 |
|
|
2016
Q4 | $120M | Sell |
327,801
-7,325
| -2% | -$2.79M | 0.14% | 170 |
|
|
2016
Q3 | $135M | Sell |
335,126
-154,568
| -32% | -$62M | 0.15% | 157 |
|
|
2016
Q2 | $171M | Buy |
489,694
+15,984
| +3% | +$6.16M | 0.19% | 112 |
|
|
2016
Q1 | $171M | Buy |
473,710
+43,416
| +10% | +$17.9M | 0.2% | 114 |
|
|
2015
Q4 | $234M | Sell |
430,294
-6,613
| -2% | -$3.58M | 0.27% | 80 |
|
|
2015
Q3 | $203M | Sell |
436,907
-331,557
| -43% | -$178M | 0.22% | 93 |
|
|
2015
Q2 | $392M | Sell |
768,464
-114,731
| -13% | -$56M | 0.38% | 59 |
|
|
2015
Q1 | $399M | Sell |
883,195
-53,092
| -6% | -$22.5M | 0.38% | 56 |
|
|
2014
Q4 | $384M | Sell |
936,287
-163,499
| -15% | -$64.3M | 0.37% | 59 |
|
|
2014
Q3 | $396M | Sell |
1,099,786
-38,227
| -3% | -$12.8M | 0.39% | 56 |
|
|
2014
Q2 | $321M | Buy |
1,138,013
+38,965
| +4% | +$11.5M | 0.32% | 67 |
|
|
2014
Q1 | $330M | Buy |
1,099,048
+83,859
| +8% | +$25.8M | 0.35% | 63 |
|
|
2013
Q4 | $279M | Buy |
1,015,189
+652,839
| +180% | +$188M | 0.32% | 71 |
|
|
2013
Q3 | $113M | Buy |
362,350
+9,081
| +3% | +$2.39M | 0.14% | 172 |
|
|
2013
Q2 | $79.4M | Buy |
+353,269
| New | +$82.3M | 0.1% | 231 |
|
Other funds holding REGN
UBS AM's REGN Position: Q2 2026 in Review
UBS AM reduced its Regeneron Pharmaceuticals (REGN) stake by 0.98% in Q2 2026, selling an estimated $4.81M and leaving 716,560 shares worth $447M. The position accounts for 0.08% of the portfolio, ranked #204.
UBS AM first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $891M in Q2 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- UBS AM held 716,560 shares of Regeneron Pharmaceuticals worth $447M as of Q2 2026.
- UBS AM sold 7,061 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.81M.
- Regeneron Pharmaceuticals made up 0.08% of UBS AM's portfolio in Q2 2026, its #204 holding.
- UBS AM first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- UBS AM's Regeneron Pharmaceuticals position peaked at $891M in Q2 2024.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.